Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)

Conditions

Infectious diseases

Brief summary

To evaluate the safety of discontinuing antibiotics by comparing the proportion of febrile neutropenia episodes with uncomplicated resolution at 28 days between the experimental group and the control group.

Detailed description

Days with fever., Days and type of antimicrobials administered., Days of neutropenia., Patient characteristics: age, sex, underlying disease, treatment phase, days since last chemotherapy cycle, type of catheter, clinical characteristics, physical examination, hours of fever on admission, vital signs, admission to paediatric ICU, risk stratification, Laboratory values (at the start of the FN episode, at 48-72 hours, at 5 days - if applicable - and at 28 days): complete blood count, serum biochemistry (see Appendix II), CRP, PCT., IL-8 (at the onset of NF and at 48-72 hours), Microbiological results: blood cultures and urine cultures and others if performed (nasopharyngeal swab, cerebrospinal fluid culture, etc.)., Results of B-HCG in urine., Imaging test results: X-ray, CT, MRI, ultrasound, among others., Incidence and severity of adverse events, Concomitant medication

Related papers

No related papers found yet.

Papers published before 2002-11-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGCEFEPIME

DRUGTEICOPLANIN

DRUGMETRONIDAZOLE

DRUGMEROPENEM

DRUGTAZOBACTAM

DRUGVANCOMYCIN

DRUGLEVOFLOXACIN

DRUGCIPROFLOXACIN

DRUGCEFTAZIDIME

DRUGAMIKACIN

DRUGPIPERACILLIN

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
To evaluate the safety of discontinuing antibiotics by comparing the proportion of febrile neutropenia episodes with uncomplicated resolution at 28 days between the experimental group and the control group.	—

Secondary

Measure	Time frame
Days with fever., Days and type of antimicrobials administered., Days of neutropenia., Patient characteristics: age, sex, underlying disease, treatment phase, days since last chemotherapy cycle, type of catheter, clinical characteristics, physical examination, hours of fever on admission, vital signs, admission to paediatric ICU, risk stratification, Laboratory values (at the start of the FN episode, at 48-72 hours, at 5 days - if applicable - and at 28 days): complete blood count, serum biochemistry (see Appendix II), CRP, PCT., IL-8 (at the onset of NF and at 48-72 hours), Microbiological results: blood cultures and urine cultures and others if performed (nasopharyngeal swab, cerebrospinal fluid culture, etc.)., Results of B-HCG in urine., Imaging test results: X-ray, CT, MRI, ultrasound, among others., Incidence and severity of adverse events, Concomitant medication	—

Measure

Time frame

Days with fever., Days and type of antimicrobials administered., Days of neutropenia., Patient characteristics: age, sex, underlying disease, treatment phase, days since last chemotherapy cycle, type of catheter, clinical characteristics, physical examination, hours of fever on admission, vital signs, admission to paediatric ICU, risk stratification, Laboratory values (at the start of the FN episode, at 48-72 hours, at 5 days - if applicable - and at 28 days): complete blood count, serum biochemistry (see Appendix II), CRP, PCT., IL-8 (at the onset of NF and at 48-72 hours), Microbiological results: blood cultures and urine cultures and others if performed (nasopharyngeal swab, cerebrospinal fluid culture, etc.)., Results of B-HCG in urine., Imaging test results: X-ray, CT, MRI, ultrasound, among others., Incidence and severity of adverse events, Concomitant medication

—

Outcome results

None listed